Trial Profile
A clinical study of NI007 for the treatment of COVID-19
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2020
At a glance
- Drugs NI 007 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 07 Apr 2020 New trial record
- 31 Mar 2020 According to a Neurimmune Therapeutics media release, the company expects to begin clinical testing in the fourth quarter of 2020, pending regulatory approval.
Most Recent Events
Trial Overview
Purpose
This study will evaluate NI 007.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations Neurimmune Therapeutics
Trial Dates
-
Initiation Dates
Planned : 01 Oct 2020
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| NI 007Primary Drug | Inhalation |
-
|
NI007
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 07 Apr 2020 | New trial record | New trial record Updated 07 Apr 2020 |
| 31 Mar 2020 | Other trial event | According to a Neurimmune Therapeutics media release, the company expects to begin clinical testing in the fourth quarter of 2020, pending regulatory approval. Updated 07 Apr 2020 |
References
-
Neurimmune Therapeutics, Ethris. Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG